

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

22 Jul 2026

### Evaluation of therapeutic effect of pro biotic medication on oral recurrent aphtus ulcers

#### Protocol summary

##### Study aim

Determination of the effect of probiotic medication produced by *Lactobacillus reuteri* on minor oral aphtus ulcers

##### Design

Clinical trials with parallel groups include the control group and the intervention group. By selecting 40 eligible patients, 20 patients in the control group and 20 patients in the intervention group will be randomly assigned to the cluster randomized. This study was designed in Phase 2-3 clinical trials.

##### Settings and conduct

This study was designed to investigate the effects of alternative therapies for oral pest infections. The plan will be conducted at Shiraz University of Medical Sciences.

##### Participants/Inclusion and exclusion criteria

inclusion criteria : patients with oral aphtus ulcers between 15 -80 years old. patients with oral aphtus ulcers without any systemic medication during last 6 months. patients with one to three oral aphtus ulcers in their mouths Patients with oral lesions that do not have a day off at the beginning of the lesion (the lesion is on the first day of appearance) Patients with oral lesions that do not have a history of rheumatologic disease, GI disease, renal disease, and iron deficiency anemia. exclusion criteria : Patients with oral aphtus lesions that have had a lesion more than one day. pregnant patients Patients with diffuse oral lesions and more than 3 concurrent lesions Patients who do not have the opportunity to travel for frequent or repeated examinations.

##### Intervention groups

In the control group, oral lesions relief by standard analgesic oral mouth rinse and the intervention group use the pro biotic medication is used as a lactobacillus strain (*lactobacillus reuteri*) in gel form.

##### Main outcome variables

The size of the lesions in millimeters Severity of burning and pain based on visual analogue score (VAS) (score

between 0-10) Duration of recovery in terms of number of days

#### General information

##### Reason for update

##### Acronym

RAS or recurrent aphtus stomatitis

##### IRCT registration information

IRCT registration number: **IRCT20110428006322N2**

Registration date: **2019-10-17, 1398/07/25**

Registration timing: **registered\_while\_recruiting**

Last update: **2019-10-17, 1398/07/25**

Update count: **0**

##### Registration date

2019-10-17, 1398/07/25

##### Registrant information

##### Name

Mostafa Rezaee

##### Name of organization / entity

Shiraz University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 71 1635 6681

##### Email address

rezaim@sums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2019-07-23, 1398/05/01

##### Expected recruitment end date

2019-11-06, 1398/08/15

##### Actual recruitment start date

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Evaluation of therapeutic effect of pro biotic medication on oral recurrent aphthous ulcers

**Public title**

probiotic on oral aphthous ulcers

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

patients with oral aphthous ulcers between 15 -80 years old. patients with oral aphthous ulcers without any systemic medication during last 6 months. patients with one to three oral aphthous ulcers in their mouths Patients with oral lesions that do not have a day off at the beginning of the lesion (the lesion is on the first day of appearance) Patients with oral lesions that do not have a history of rheumatologic disease, GI disease, renal disease, and iron deficiency anemia.

**Exclusion criteria:**

Patients with oral aphthous lesions that have had a lesion more than one day. pregnant patients Patients with diffuse oral lesions and more than 3 concurrent lesions Patients who do not have the opportunity to travel for frequent or repeated examinations.

**Age**

No age limit

**Gender**

Both

**Phase**

2-3

**Groups that have been masked**

- Participant
- Investigator
- Outcome assessor

**Sample size**Target sample size: **40**

More than 1 sample in each individual

Number of samples in each individual: **20**

In the control group, oral lesions relief by standard analgesic oral mouth rinse and the intervention group use the pro biotic medication is used as a lactobacillus strain (lactobacillus reuteri) in gel form.

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

clustered block randomization ,To ensure that exactly the same number of participants were placed in the intervention and control groups at regular intervals but at equal intervals, we considered the size of each block as 10 individuals. For example, one type of treatment or intervention will be occurred to the first block and the other intervention or treatment to the second block and again the same cycle until the last block. In this study we have 3 to blocks that include 10 individuals.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

In this study, patients and assessors or examiners are not aware of the type of treatment provided. The patient receives treatment from the beginning, which is unclear whether the treatment is new or the standard treatment (on the other hand) and the examiner does not need to know what medicine the patient has used, it only records the information.

**Placebo**

Not used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics committee of Shiraz University of Medical Sciences

**Street address**

Ghasr-e-Dasht St., Corner of Mehr St., Shiraz Dental School

**City**

Shiraz

**Province**

Fars

**Postal code**

1587871956

**Approval date**

2019-09-08, 1398/06/17

**Ethics committee reference number**

IR.SUMS.DENTAL.REC.1398.103

**Health conditions studied****1****Description of health condition studied**

oral recurrent aphthous ulcer

**ICD-10 code**

K12

**ICD-10 code description**

Stomatitis and related lesions

**Primary outcomes****1****Description**

The size of the lesions in millimeters

**Timepoint**

determination at 1,3,5 and 7 days

**Method of measurement**

size determination by ruler

## 2

### **Description**

Severity of burning and pain based on visual analogue score (VAS) (score between 0-10)

### **Timepoint**

determination at 1,3,5 and 7 days

### **Method of measurement**

Evaluation by VAS method and numerical expression of pain and burning intensity

## 3

### **Description**

Duration of recovery in terms of number of days

### **Timepoint**

daily check for seven days

### **Method of measurement**

Improvement of clinical symptoms, absence of oral lesions and complete relief of burning and pain

## **Secondary outcomes**

empty

## **Intervention groups**

## 1

### **Description**

Intervention group: Treatment with probiotic product or probiotic products from *Lactobacillus routeri* is administered in a gel-sol form, which patients put in the mouth on the lesion and should not swallow the drug. The drug is formulated in the Biotechnology and Pharmacotechnics department of Shiraz Pharmacy School and is not a mass production or drug owned by a particular pharmaceutical company. The product should be applied 3 times daily to the oral lesion for at least 2-3 minutes for 10 days. The product is based on the drug protocols and approved drug standards at the School of Pharmacy and its route of manufacture is part of the process of this study. The content of this drug is merely a probiotic product, and the drug is in the form of a gel-sol form, a relatively diluted state that makes it easier for the patient to use the drug. Use of probiotic products in the pharmaceutical process Considering that they are used in many nutritional supplement products and offer immune-enhancing or immune-enhancing roles, they are considered safe products in most pharmaceutical supplements.

### **Category**

Treatment - Drugs

## 2

### **Description**

Control group: receive standard analgesic treatment for treatment ( Standard compound oral mouthwash with analgesic effect) , For the control group patients receive conventional topical analgesics, including Diphenhydramine syrup + Aluminum Mg suspension (both manufactured by Iran Pakhsh Pharmacopoeia Iran)

with a ratio of one to one, and a similar container is given to the intervention group. The drug is prescribed 3 times a day for 10 days.

### **Category**

Treatment - Drugs

## **Recruitment centers**

## 1

### **Recruitment center**

#### **Name of recruitment center**

Dental faculty of Shiraz University of Medical Sciences

#### **Full name of responsible person**

Mostafa Rezaee

#### **Street address**

Ghasr-e-Dasht St., Corner of Mehr St., Shiraz Dental School

#### **City**

Shiraz

#### **Province**

Fars

#### **Postal code**

1587871956

#### **Phone**

+98 71 3628 9917

#### **Email**

rezaim@sums.ac.ir

## **Sponsors / Funding sources**

## 1

### **Sponsor**

#### **Name of organization / entity**

Shiraz University of Medical Sciences

#### **Full name of responsible person**

Dr . Yonnes Ghasemi

#### **Street address**

Ghasr-e-Dasht St., Corner of Mehr St., Shiraz Dental School

#### **City**

Shiraz

#### **Province**

Fars

#### **Postal code**

1587871956

#### **Phone**

+98 71 3628 9917

#### **Email**

rezaim@sums.ac.ir

### **Grant name**

### **Grant code / Reference number**

### **Is the source of funding the same sponsor organization/entity?**

Yes

### **Title of funding source**

Shiraz University of Medical Sciences

### **Proportion provided by this source**

80

### **Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Mostafa Rezaee

**Position**

Associate professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Dentistry

**Street address**

Ghasr-e-Dasht St., Corner of Mehr St., Shiraz Dental School

**City**

Shiraz

**Province**

Fars

**Postal code**

1587871956

**Phone**

+98 71 3628 9917

**Email**

rezaim@sums.ac.ir

**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Mostafa Rezaee

**Position**

Associate professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Dentistry

**Street address**

Ghasr-e-Dasht St., Corner of Mehr St., Shiraz Dental School

**City**

Shiraz

**Province**

Fars

**Postal code**

1587871956

**Phone**

+98 71 3628 9917

**Email**

rezaim@sums.ac.ir

**Person responsible for updating data****Contact****Name of organization / entity**

Shiraz University of Medical Sciences

**Full name of responsible person**

Mostafa Rezaee

**Position**

Associate professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Dentistry

**Street address**

Ghasr-e-Dasht St., Corner of Mehr St., Shiraz Dental School

**City**

Shiraz

**Province**

Fars

**Postal code**

1587871956

**Phone**

+98 71 3628 9917

**Email**

rezaim@sums.ac.ir

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Yes - There is a plan to make this available

**Data Dictionary**

Not applicable

**Title and more details about the data/document**

In this study, due to the confidentiality of the individual data of the participants, only the executive protocol, data analysis method, and general plan information are shared in the article.

**When the data will become available and for how long**

starting 6 months after publication

**To whom data/document is available**

this only available for people working in academic institutions

**Under which criteria data/document could be used**

only for research propose

**From where data/document is obtainable**

email address

**What processes are involved for a request to access data/document**

Send an email to the planner and contact person to receive the required information. In the absence of the

problem, the information required will be less than 2 weeks

**Comments**  
no